N on-ST-segment-elevation myocardial infarction (NSTEMI) affects >625 000 patients annually or almost three fourths of all patients with acute coronary syndromes 1 and is associated with significant morbidity and mortality.
Bivalirudin Use for NSTEMI in the United States
As such, bleeding avoidance strategies to reduce periprocedural events have become increasingly important components of modern PCI practice. 9, 10 Bivalirudin, a direct thrombin inhibitor, was found in randomized trials to reduce bleeding and possibly improve mortality after PCI. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] This has resulted in its inclusion in current NSTEMI guidelines as the preferred agent for patients deemed to be at high risk of bleeding. 2 The absolute benefit of bivalirudin therapy over unfractionated heparin (UFH) among patients with NSTEMI has been challenged. Contemporary bivalirudin trials have primarily involved patients with ST-segment-elevation myocardial infarction (STEMI), [12] [13] [14] 16 a population that has greater post-procedure ischemic 20 and bleeding 21 events. In addition, most trials involving patients with NSTEMI compared bivalirudin with UFH coadministered with a glycoprotein IIb/IIIa inhibitor (GPI). [17] [18] [19] GPIs are associated with decreased ischemic events, increased bleeding, and possibly improved mortality, 22, 23 and in current practice are typically reserved for provisional use with UFH during PCI. 2, 11 Clinical trials have also used exclusion criteria that may have restricted enrollment of the highest risk patients, thereby concealing certain risks or benefits of bivalirudin therapy.
We designed this study with 3 purposes: (1) to examine trends in use of bivalirudin-and UFH-based anticoagulant regimens during PCI for NSTEMI in the United States; (2) to determine the comparative effectiveness of bivalirudin therapy versus UFH on in-hospital bleeding and mortality, allowing for the unbalanced use of GPIs with UFH as seen in clinical practice; and (3) to assess the extent to which differences in outcomes with bivalirudin-and UFH-based regimens are driven by higher rates of GPI use with UFH.
Methods

Data Set and Patient Selection
The National Cardiovascular Data Registry CathPCI Registry was used to derive the patient cohort. Data from PCIs performed between July 1, 2009, and December 31, 2014, for the indication of NSTEMI were analyzed. For the CathPCI Registry, NSTEMI is defined as the presence of both the following criteria: (1) cardiac biomarkers exceeding the upper limit of normal with a clinical presentation which is consistent or suggestive of ischemia; and (2) the absence of electrocardiographic changes diagnostic of STEMI. All PCIs performed for NSTEMI with a valid operator identifier were included. The only other exclusion criterion was use of anticoagulants besides bivalirudin or UFH, including low molecular weight heparin, fondaparinux, and nonbivalirudin direct thrombin inhibitors ( Figure I in the Data Supplement). Waiver of written informed consent and authorization for this study was granted by Chesapeake Research Review Incorporated.
Study Outcomes
In-hospital bleeding and in-hospital mortality were the primary outcome measures for this analysis. In-hospital bleeding was based on the National Cardiovascular Data Registry version 4 definition, 24 which included any of the following occurring before hospital discharge: arterial access site bleeding; retroperitoneal, gastrointestinal, or genitourinary bleeding; intracranial hemorrhage; cardiac tamponade; post-procedure hemoglobin decrease of 3 g/dL in patients with a pre-procedure hemoglobin level ≤16 g/dL; or post-procedure nonbypass surgery-related blood transfusion for patients with a preprocedure hemoglobin level ≥8 g/dL. Secondary end points included access site bleeding, nonaccess site bleeding, need for red blood cell (RBC) transfusion, and repeat PCI for stent thrombosis (eMethods I in the Data Supplement). The outcome repeat PCI for stent thrombosis was constructed for this analysis and was defined as a subsequent PCI performed during the same index hospitalization as the NSTEMI-related PCI for the indication of stent thrombosis.
Patient, Procedural, and Operator Characteristics
Patient and procedural characteristics among patients receiving bivalirudin versus UFH were identified at the time of the index PCI. These variables included sociodemographic characteristics, medical history, presentation characteristics, and procedural variables (eMethods II in the Data Supplement). Operator factors, including practice region and annual PCI volume, were also evaluated. All variables were used for adjustment in the statistical models.
Statistical Analysis
To assess for variations in temporal trends in anticoagulant strategies, we evaluated the proportions of patients with NSTEMI treated with 1 of 4 regimens during each calendar quarter. These strategies included bivalirudin monotherapy, bivalirudin with GPI, UFH monotherapy, and UFH with GPI. Linear regression was used to test for differences in the proportions of each anticoagulant regimen during the study period. Individual operator heterogeneity in anticoagulant use was also analyzed and determined by each operator's proportional use of bivalirudin during all NSTEMI PCIs. For all analyses, use of bivalirudin could include the coadministration of UFH, whereas use of UFH excluded concomitant bivalirudin use.
We used 2 statistical approaches to compare the effectiveness between bivalirudin and UFH strategies. First, we conducted a propensity score (PS)-based analysis, which relies on adjustment through matching by measured covariates. To construct the PS for administering bivalirudin, we used all patient and procedural characteristics, as found in Tables 1 and 2 , and fit logistic regression models with bivalirudin use as a response variable. GPI use was excluded as a variable in creation of the PS to preserve how GPIs are administered in clinical practice. In addition, matching on GPI use would likely bias the sample by selectively including bivalirudin patients who were coadministered GPIs, a practice that is not guideline recommended.
25
WHAT IS KNOWN
• Bivalirudin, a direct thrombin inhibitor, has been found in randomized trials to reduce bleeding and possibly improve mortality after PCI in patients with NSTEMI.
• Most randomized trials involving patients with NSTEMI compared bivalirudin with UFH in patients receiving transfemoral access and a GPI, an agent associated with increased bleeding.
WHAT THE STUDY ADDS
• This study, the largest comparative analysis of bivalirudin versus UFH for NSTEMI to date, demonstrates that bivalirudin is associated with decreased in-hospital bleeding and mortality after PCI.
• The clinical benefit associated with bivalirudin is, in part, explained by the greater use of GPIs with UFH and is also determined by the site of arterial access, with patients experiencing negligible reductions in bleeding when undergoing transradial PCI.
• These results should be used to better inform clinicians to patient scenarios in which bivalirudin use may provide the greatest reduction in post-PCI adverse events.
We matched 231 226 bivalirudin recipients in a 1:1 fashion with UFH recipients by using the greedy matching technique, with high balance in characteristics between groups (eTables I and II in the Data Supplement). We used linear regression models applied on the matched population to calculate the absolute risk difference (RD) associated with bivalirudin use for each outcome. This allowed for the estimation of RDs as similarly calculated in the instrumental variable (IV) analysis. Second, we performed an IV analysis to account for treatment selection bias and unmeasured confounding that are often incompletely controlled for by traditional statistical methods used in observational analyses 26 (eMethods III in the Data Supplement). For the IV, a preference-based instrument, 27 namely an operator's proportional use of bivalirudin, was used as the instrument because selection of anticoagulant strategy during PCI for NSTEMI is currently at the discretion of the operator. 2 High bivalirudin operators were defined as those who administered bivalirudin equal to or greater than the median use among all operators. Low bivalirudin operators were those who administered bivalirudin less than the median among all operators. Application of the instrument resulted in high balance in patient, procedural, and operator characteristics between high and low bivalirudin operators (eTables III-V in the Data Supplement). The instrument was also predictive of actual treatment with bivalirudin (high operator bivalirudin use: 86.2% of all PCIs; low operator bivalirudin use: 29.3% of all PCIs).
The IV analysis was then performed using a standardized approach, the 2-stage least squares methodology 26 (eMethods III in the Data Supplement). This involved the construction of 2 sequential linear regression models, with the final output being the treatment effect with bivalirudin on the absolute scale. Models from each stage BMI indicates body mass index; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; GFR, glomerular filtration rate; HF, heart failure; IQR, interquartile range; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; and PCI, percutaneous coronary intervention.
*Significance is defined by a standardized difference >10%. Bivalirudin Use for NSTEMI in the United States included adjustment for all patient, procedural, and operator characteristics. Given the large sample size, a standardized difference with a cutoff of >10% was used to compare differences in patient characteristics between groups. 28 We additionally used the IV to perform a test of mediation to measure the absolute influence of differential use of GPIs on outcomes. To do so, we first performed the IV without controlling for GPI therapy, as described previously. This allowed for us to compare outcomes between the most commonly used bivalirudin-based anticoagulation strategy (12.0% use of GPIs) and the most commonly used UFH-based strategy (50.5% use of GPIs), analogous to allowing operators to use GPIs at their discretion in a randomized clinical trial analyzed by the intention-to-treat principle. 13, 29 We then re-estimated treatment effects after additionally adjusting for GPI use, which allowed us to measure the extent to which our primary findings were driven by differences in GPI use between treatment groups.
As a pre-specification, we stratified all analyses based on use of radial versus femoral arterial access because access site is known to interact with both bleeding and mortality after PCI. 30 A 2-sided P value with a threshold of <0.05 was used for statistical significance. Statistical analyses were performed using SAS software v9.3 (SAS Institute, Cary, NC). At the beginning of the analysis, bivalirudin monotherapy was administered in 37.3% of all procedures, and UFH was used with a GPI in 35.8% and without a GPI in 17.9% (Figure 1 ). Use of bivalirudin monotherapy increased from this time through the first quarter of 2014, with a peak use of 57.0% (P<0.01 for trend). This was paralleled by a decline in use of UFH with GPI (14.4% Q1 2014; P<0.01 for trend). Beginning in the second quarter of 2014, there was a decline in bivalirudin monotherapy use, which persisted through the end of the year (48.0% Q4 2014). This was mirrored by an increase in use of UFH monotherapy (22.1% Q1 2014; 31.7% Q4 2014; P<0.01 for trend). Bivalirudin was infrequently administered with a GPI throughout the study period (9.04% Q3 2009; 5.17% Q4 2014).
Results
Temporal Trends in Use of Anticoagulant Regimens
Variation in Use by Individual Operators
Operators demonstrated significant individual variation in use of bivalirudin during PCI (Figure 2 ). During the study period, the highest quartile of bivalirudin operators administered bivalirudin in ≥88.5% of all PCIs, whereas the lowest quartile bivalirudin operators used bivalirudin in ≤27.8% of all PCIs.
Characteristics and Outcomes Between Bivalirudin and UFH Recipients
Patients treated with bivalirudin compared with UFH were of similar age, sex, and race (Table 1 ). In addition, there were nonsignificant differences in rates of cardiovascular risk factors and prior cardiovascular disease between treatment groups. During the index procedure, patients receiving bivalirudin were more likely to receive PCI via transfemoral access (Table 2) . Otherwise, there were no significant differences in procedural characteristics between groups, including type of stent received, lesion risk, number of vessels receiving intervention, and total number of stents placed.
Unadjusted Treatment Effects
Among the study population, 6.84% had an in-hospital bleed (2.06% with access site bleeding, 0.56% with nonaccess site bleeding, and 3.77% with red blood cell transfusion), 1.97% experienced an in-hospital death, and 0.23% required repeat PCI for stent thrombosis (eTable VI in the Data Supplement). Bivalirudin versus UFH use was associated with lower inhospital bleeding (5.65% versus 8.33%; RD, −2.68%; 95% confidence interval [CI]: −2.82%, −2.55%; P<0.01), access site bleeding (1.62% versus 2.60%; RD, −0.99%; 95% CI: −1.07%, −0.92%; P<0.01), nonaccess site bleeding (0.44% versus 0.70%; RD, −0.26%; 95% CI: −0.30%, −0.22%; P<0.01), and need for red blood cell transfusion (3.21% versus 4.47%; RD, −1.27%; 95% CI: −1.37%, -1.17%; P<0.01; Figure 3 ; eTable VI in the Data Supplement). In addition, patients receiving bivalirudin had lower in-hospital mortality (1.65% versus 2.38% with UFH; RD, −0.75%; 95% CI: −0.82%, -0.67%; P<0.01) but had a slightly greater need for repeat PCI for stent thrombosis (0.25% versus 0.21% with UFH; RD, 0.03%; 95% CI: 0.01%, 0.06%; P=0.02). Rates of outcomes stratified by arterial access site are shown in Figure 3B and 3C.
Adjusted Treatment Effects
PS and IV methodologies resulted in similar absolute estimates of treatment effects associated with bivalirudin use (Figure 3 ; eTables VII and VIII in the Data Supplement). Before Decreases in access site bleeding, nonaccess site bleeding, and need for red blood cell transfusion were also significant with bivalirudin use ( Figure 3A ; eTables VII and VIII in the Data Supplement) as was the greater need for repeat PCI for stent thrombosis (PS: RD, 0.03%; 95% CI: 0.00%, 0.06%; number needed to harm [NNH], 3572; P=0.048; IV: RD, 0.06%; 95% CI: 0.01%, 0.10%; NNH, 1719; P=0.01).
Among PCIs performed via radial arterial access and before adjustment for unbalanced GPI use ( Figure 3B ), the bleeding effect associated with bivalirudin was attenuated but remained significant (PS: RD, −0.69%; 95% CI: −0.94%, −0.45%; NNT, 145; P<0.01; IV: RD, −0.50%; 95% CI: −0.86%, −0.13%; NNT, 201; P<0.01). However, bivalirudin was no longer associated with improved survival (PS: RD, −0.01%; 95% CI: −0.13%, 0.11%; P=0.85; IV: RD, −0.11%; 95% CI: −0.28%, 0.06%; P=0.21). Conversely, among patients receiving PCI via femoral arterial access, treatment effects associated with bivalirudin were of larger magnitude ( Figure 3C) , with an absolute risk reduction in bleeding ranging from 2.44% (IV: 95% CI: 2.18%, 2.71%; NNT, 41; P<0.01) to 2.65% (PS: 95% CI: 2.48%, 2.82%; NNT, 38; P<0.01) and a risk reduction in mortality ranging from 0.20% (IV: 95% CI: 0.05%, 0.34%; NNT, 513; P<0.01) to 0.31% (PS: 95% CI: 0.21%, 0.40%; NNT, 328; P<0.01). Bivalirudin use also remained associated with decreases in access site bleeding, nonaccess site bleeding, and need for transfusion among those undergoing transfemoral PCI yet was not associated with an increased need for repeat PCI for stent thrombosis ( Figure 3C ).
Impact of Differential Use of GPIs on Outcomes
The greater use of GPIs with UFH accounted for more than half the bleeding reduction associated with bivalirudin in the IV (before GPI adjustment: RD, −2.04%; 95% CI: −2.27%, −1.81%; NNT, 50; P<0.01; after GPI adjustment: RD, −0.84%; 95% CI: −1.11%, −0.57%; NNT, 120; P<0.01; Figure 4A ). The remaining bleeding reduction was primarily driven by decreases in access site bleeding (RD, −0.29%; 95% CI: −0.45%, −0.13%; NNT, 343; P<0.01) and need for transfusion (RD, −0.56%; 95% CI: −0.77%, −0.35%; NNT, 179; P<0.01). Conversely, there was no longer an association between bivalirudin use and in-hospital mortality after accounting for differential GPI use (RD, −0.10%; 95% CI: −0.24%, 0.05%; P=0. 19) . Irrespective of GPI administration, there remained a small increase in the need for repeat PCI for stent thrombosis (before GPI adjustment: RD, 0.06%; 95% CI: 0.01%, 0.10%; NNH, 1719; P=0.01; after GPI adjustment: RD, 0.07%; 95% CI: 0.01%, 0.12%; NNH, 1491; P=0.02).
After accounting for the unbalanced use of GPIs among those receiving PCI via transradial access, there was no association between bivalirudin treatment and any of the outcomes (bleeding: before GPI adjustment, RD, −0.50%; 95% CI: −0.86%, −0.13%; NNT, 201; P<0.01; after GPI adjustment, RD, 0.09%; 95% CI: −0.32%, 0.50%; P=0.66; mortality: before GPI adjustment, RD, −0.11%; 95% CI: −0.28%, 0.06%; P=0.21; after GPI adjustment, RD, −0.10%; 95% CI: −0.30%, 0.09%; P=0.30; Figure 4B ). However, when transfemoral access was used, there was an attenuated but significant association between bivalirudin and decreased bleeding (before GPI adjustment, RD, −2.44%; 95% CI: −2.71%, −2.18%; NNT, 41; P<0.01; after GPI adjustment, RD, −1.11%; 95% CI: −1.43%, −0.80%; NNT, 90; P<0.01; Figure 4C ). This was driven primarily by reductions in access site bleeding (RD, −0.40%; 95% CI: −0.59%, −0.22%; NNT, 248; P<0.01) and need for transfusion (RD, −0.74%; 95% CI: −0.97%, −0.50%; NNT, 136; P<0.01). BMS indicates bare metal stent; DES, drug eluting stent; IABP, intra-aortic balloon pump; IQR, interquartile range; mLAD, mid left anterior descending; PCI, percutaneous coronary intervention; pCIRC, proximal circumflex; pLAD, proximal left anterior descending; and pRCA, proximal right coronary artery.
*Significance is defined by a standardized difference >10%. Bivalirudin Use for NSTEMI in the United States
Discussion
Analyzing data from >500 000 PCIs performed for NSTEMI throughout the United States between 2009 and 2014, we made the following observations. First, bivalirudin was the most commonly used anticoagulant during PCI for NSTEMI although there was a decline in use during 2014. Second, bivalirudin use relative to UFH with or without the coadministration of a GPI corresponded with decreased in-hospital bleeding. Bleeding reductions were largest among those undergoing transfemoral PCI and attenuated among those treated with transradial PCI. Third, reductions in bleeding with bivalirudin were largely, but not completely, because of the greater use of GPIs with UFH. Last, bivalirudin was associated with improved in-hospital mortality when GPIs were administered without restriction (51% with UFH versus 12% with bivalirudin), but this association was eliminated among patients treated via transradial access and when analyses adjusted for differences in GPI use.
Temporal Changes in Bivalirudin Use
As of 2009, bivalirudin became the most frequently administered anticoagulant during PCI for NSTEMI in the United States, 31 and as observed in the current study, remained so through 2014. However, we noted a decline in bivalirudin use during 2014, which was replaced by greater use of UFH monotherapy. Although there were no further bivalirudin trials in patients with NSTEMI to correspond with this timing, we hypothesize multiple factors that likely influenced this change in practice. First, during this period, there had been a growing use of transradial arterial access and decreasing use of GPI therapy, 31 practices which are associated with reduced periprocedural bleeding. Second, there was new concern over the association between bivalirudin therapy and acute stent thrombosis, which had manifested in 2 large bivalirudin STEMI trials. 13, 15 Finally, the timing of decline in bivalirudin use corresponded with the presentation of the How Effective Are Antithrombotic Therapies in Primary Percutaneous 12 a single center study of patients with STEMI that found no difference in major bleeding, but an increase in the composite ischemic end point with bivalirudin versus UFH monotherapy. Although How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention involved only patients with STEMI, its findings were notable because the trial included prevalent use of transradial access (>85%) and low use of adjunctive GPI (<15%).
Effectiveness of Bivalirudin During PCI for NSTEMI
Using nationwide clinical data to compare the effectiveness of bivalirudin with UFH, we found that bivalirudin use was associated with a 2% reduction in bleeding (NNT, 50), results that are comparable to previous trial data. [17] [18] [19] The more frequent use of GPIs with UFH accounted for more than half of this relationship, yet even after adjustment, bivalirudin remained associated with decreased bleeding (0.84%; NNT, 120). The bleeding reduction with bivalirudin was driven by decreases in access site bleeding (0.29%) and need for transfusion (0.56%) and was most significant among those undergoing transfemoral PCI (1.11%). Contrarily, among patients receiving transradial access, we found no bleeding benefit with bivalirudin after GPI adjustment. These results are supported by prior analyses of pooled trial data, 11, 32 but to our knowledge, have not yet been replicated using nationwide clinical data.
Bivalirudin was also associated with improved survival, both in unadjusted analysis (0.75% reduction; NNT, 134) and Note that among all PCIs (A), after GPI adjustment, bleeding reductions were more than halved and the mortality benefit associated with bivalirudin was no longer apparent. In addition, accounting for GPI use among patients receiving transradial PCI negated any benefit of bivalirudin treatment as compared with unfractionated heparin (B). However, a bleeding benefit with transfemoral access persisted after GPI adjustment (C). Error bars represent 95% confidence intervals. RBC indicates red blood cell. Bivalirudin Use for NSTEMI in the United States in adjusted analyses that did not include GPI use as a covariate (0.25% reduction; NNT, 397). A mortality benefit with bivalirudin therapy had previously been observed in trials involving patients with STEMI 15 and those presenting with acute coronary syndromes 29 and is thought to be related to decreased nonaccess site and fatal bleeding. 29 Notably, after we accounted for the disproportionate use of GPIs, which were frequently used with UFH in both these trials, this mortality reduction was no longer apparent. This occurred in conjunction with a sizable decrease in bivalirudin's bleeding reduction. Although it is unclear whether and to what degree GPI administration is associated with survival in this study, it is possible that the short-term mortality benefit with bivalirudin may, in part, be a consequence of increased bleeding related to the greater use of GPIs with UFH.
We observed only a small increase in the need for repeat PCI for the indication of in-hospital stent thrombosis associated with bivalirudin (0.06%). This occurred regardless of GPI adjustment. The risk of acute stent thrombosis related to bivalirudin has been demonstrated in several trials primarily involving patients with STEMI 13, 15 and has been theorized to be driven by factors such as post-PCI bivalirudin dosing and infusion duration, and loading time and type of oral antiplatelet agent. Although we cannot fully account for these factors in the current analysis, we do note that the overall risk we observed was small, with an NNH of >1400.
Overall, these findings suggest that bivalirudin therapy is beneficial among patients undergoing PCI for NSTEMI. However, the influence of arterial access site and GPI therapy is notable, and as practice patterns continue to evolve (ie, increasing radial use and decreasing GPI use), the optimal role of bivalirudin may become more selective, such as for patients requiring transfemoral access.
Treatment Effects of Bivalirudin in NSTEMI Versus STEMI
Treatment effects associated with bivalirudin in patients presenting with NSTEMI were similar to observations we made in the STEMI population. 33 Although the absolute magnitude of bleeding reduction was smaller among those with NSTEMI, differential GPI use accounted for more than half the bleeding effect of bivalirudin in both sets of patients. As expected, the stent thrombosis rate was lower in the NSTEMI population because STEMI itself is a known risk factor. For both populations, the benefit of bivalirudin was greatest among those receiving transfemoral access.
Limitations
The results of this analysis must be considered in the context of the study design. The CathPCI Registry does not collect data on anticoagulant doses, timing of administration, or treatment durations, all of which may be associated with post-procedural bleeding and ischemic events. For instance, we were unable to determine whether GPIs were administered as a planned strategy or provisionally or for what duration UFH was coadministered with bivalirudin. Similarly, we lacked data on the timing and loading dose of oral antiplatelet agents and cannot assess the impact of the higher potency P2Y12 inhibitors. Second, the analysis was restricted to in-hospital outcomes, whereas differences in treatment effects may become apparent with longer durations of follow-up. In addition, our study outcomes were derived from the CathPCI Registry, which does not adjudicate all events, and may have resulted in the over-or underestimation of actual event rates. Last, stent thrombosis is not a validated event in the CathPCI Registry, and the outcome repeat PCI for stent thrombosis was constructed for use in this analysis.
Conclusions
From mid-2009 through 2014, bivalirudin was the primary anticoagulant strategy used during PCI for patients presenting with NSTEMI. Overall, bivalirudin therapy was associated with decreased adverse events. The benefit of bivalirudin was in part, but not entirely, because of the greater use of GPIs with UFH. Importantly, access site was a strong determinant of the treatment effect associated with bivalirudin, with bleeding reductions largest among those receiving transfemoral access and negligible among those receiving transradial access. These observations favor the use of bivalirudin in patients with NSTEMI, particularly among those undergoing transfemoral PCI.
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